CELSION CORPORATION (NASDAQ:CLSN) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(e)Compensatory Arrangements with Certain Officers.

The Board of Directors previously adopted, subject to stockholder approval, the Celsion Corporation 2018 Stock Incentive Plan (the “2018 Plan”). At the 2018 Annual Meeting of Stockholders held on May 15, 2018, the stockholders of the Company approved the 2018 Plan. Under the 2018 Plan, the Compensation Committee of the Company’s Board of Directors may grant incentive stock options, nonqualified stock options, stock appreciation rights, phantom stock and restricted stock to all directors, officers, employees and consultants of the Company or any parent, subsidiary or affiliate of the Company. The selection of those directors, officers, employees and consultants, from among those eligible, who will receive awards under the 2018 Plan, is within the discretion of the Compensation Committee, provided that awards of incentive stock options may be made only to employees of the Company and any parent or subsidiary of the Company. An aggregate of 2,700,000 shares of common stock of the Company are available for issuance to the 2018 Plan. In addition, any shares of Company common stock reserved for issuance under the 2007 Stock Incentive Plan that were available at the time of shareholder approval of the 2018 Plan, or that become available due to the expiration or forfeiture of options granted under the 2007 Stock Incentive Plan, will be added to the pool of shares of Company common stock available under the 2018 Plan.

In the event of a Change in Control (as defined in the 2018 Plan), the Board of Directors, as constituted prior to the Change in Control, may in its discretion: (1) require that (i) options and stock appreciation rights become exercisable either immediately or upon termination of employment, (ii) the restrictions and performance measures applicable to outstanding awards lapse either immediately or upon subsequent termination of employment, or (iii) the performance measures applicable to outstanding awards are deemed satisfied at target, maximum or any other level; (2) require shares of capital stock of the resulting corporation from such Change in Control, or its parent corporation, be substituted for shares of Company common stock subject to an outstanding award; and/or (3) require outstanding awards to be surrendered to the Company by the holder and immediately cancelled by the Company, and to provide the holder (i) a cash payment as permitted under the 2018 Plan, (ii) shares of capital stock of the resulting corporation to such Change in Control, or (iii) a combination of payment of cash and issuance of shares to (3)(i) and (3)(ii) above.

The 2018 Plan will expire as of the first annual meeting of the Company’s stockholders to occur on or after the tenth anniversary, unless terminated earlier by the Board of Directors.

The foregoing description of the 2018 Plan is only a summary and is qualified in its entirety by reference to the 2018 Plan, a copy of which is attached hereto as exhibit 10.1 and is incorporated by reference herein.

At the Company’s 2018 Annual Meeting of Stockholders held on May 15, 2018, the following actions were taken. The proposals below are described in detail in the Company’s definitive proxy statement dated March 30, 2018 for the Annual Meeting.

Proposal 1

Each of the individuals listed below was elected, by a majority of the votes cast at the Annual Meeting and entitled to vote on the election of directors, to serve on the Board of Directors until the 2021 Annual Meeting of Stockholders.

In addition to the directors elected above, Mr. Michael H. Tardugno, Mr. Frederick J. Fritz, Dr. Augustine Chow, Dr. Donald P. Braun and Dr. Andreas Voss continued to serve as directors after the Annual Meeting.

Proposal 2

The proposal, by the Audit Committee of the Board of Directors of the Company, to ratify the appointment of WithumSmith + Brown, PC as the independent registered public accounting firm for the fiscal year ending December31, 2018, as described in the proxy materials, was approved with approximately 94.5% of the shares present or represented and voting at the Annual Meeting voting for the proposal and approximately 3% voting against the proposal with 2.5% abstaining.

Proposal 3

The proposal to approve the adoption of the Celsion Corporation 2018 Stock Incentive Plan was approved based on the following votes:

Item 5.02Financial Statements and Exhibits.

(d) Exhibits

Celsion CORP Exhibit
EX-10.1 2 ex_114605.htm EXHIBIT 10.1 ex_114605.htm Exhibit 10.1     CELSION CORPORATION   2018 STOCK INCENTIVE PLAN     I.     INTRODUCTION   1.1     Purposes. The purposes of the Celsion Corporation 2018 Stock Incentive Plan (this “Plan”) are (i) to align the interests of the Company’s stockholders and the recipients of awards under this Plan by increasing the proprietary interest of such recipients in the Company’s growth and success,…
To view the full exhibit click here

About CELSION CORPORATION (NASDAQ:CLSN)

Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers. It has over three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, including Lysolipid Thermally Sensitive Liposomes, a heat sensitive liposomal based dosage form that targets disease with known therapeutics in the presence of mild heat; TheraPlas, a nucleic acid-based treatment for local transfection of therapeutic plasmids, and TheraSilence, a systemic dosage form for lung directed anti-cancer ribonucleic acid (RNA).